Accelerated Access Collaborative

Executive Summary

  • The Accelerated Access Collaborative (AAC) is the decision-making body for the Accelerated Access Pathway (AAP) which arose from the Government’s Accelerated Access Review (AAR)
  • The Pathway provides a route and interim funding to enable widespread reimbursement of proven and cost-effective pharmaceuticals and medical devices
  • Products selected for this route are expected to achieve a minimum of cost-neutrality, and ideally savings, a year after launch via the AAP
  • Only licensed products (i.e. those with Marketing Authorisation) are eligible for the scheme